Citations

Clear

6273 citation(s) found for "To, Andrew".

Neurons Over Nephrons
Brinjikji, Waleed , Demchuk, Andrew M. , Murad, M. Hassan , McDonald, Robert J. , Kallmes, David F. , Murad, Mohammad H, Rabinstein, Alejandro A. , McDonald, Jennifer S. , Murad, M Hassan , Demchuk, Andrew M

Mayo Clinic

Stroke | June 6, 2017 | Volume: 48 | Issue: 7 | Pages: 1862-1868

10.1161/strokeaha.117.016771 | PMID 28583996 Get It

Background and Purpose— Because of the perceived risk of contrast-induced acute kidney injury (AKI), many centers require pre-imaging serum creatinine levels, potentially delaying care. We performed a systematic review and meta-analysis evaluating AKI rates in patients with acute ischemic stroke receiving computed tomographic angiography (CTA) and computed tomographic perfusion (CTP). Methods— We searched MEDLINE, EMBASE, and the Web of Science through December 2016 for studies reporting on AKI in patients with acute ischemic stroke receiving CTA/CTP. Using a random-effects model, estimates were pooled across studies. Outcomes of interest were (1) the odds of AKI in patients receiving CTA/CTP versus noncontrast computed tomography, (2) overall rate of AKI and hemodialysis in patients with acute ischemic stroke undergoing CTA/CTP, and (3) the odds of CTA/CTP-associated AKI among patients with and without chronic kidney disease. Results— Fourteen studies were included (6 case–control studies and 8 single-arm studies) with 5727 CTA/CTP and 981 noncontrast computed tomography patients. In case–control studies, AKI was significantly lower among CTA/CTP patients compared with noncontrast computed tomography patients (odds ratio=0.47; 95% confidence interval=0.33–0.68; P <0.01). Adjusting for baseline creatinine, there was no difference in AKI rates between groups (odds ratio=0.34; 95% confidence interval=0.10–1.21). The overall rate of AKI in CTA/CTP patients was 3% (95% confidence interval=2%–4%). The overall rate of hemodialysis in the CTA/CTP group was 0.07% (3 of 4373). There was no difference in AKI among CTA/CTP patients with and without chronic kidney disease (odds ratio=0.63; 95% confidence interval=0.34–1.12). Conclusions— Nonrandomized evidence suggests that CTA/CTP are not associated with statistically significant increase in risk of AKI in patients with stroke, even those with known chronic kidney disease.
Impact of perioperative anticoagulation on artificial urinary sphincter device survival
Blackburne, Andrew T. , Linder, Brian J. , Elliott, Daniel S. , Linder, Brian J

Mayo Clinic

Scandinavian Journal of Urology | June 5, 2017 | Volume: 51 | Issue: 4 | Pages: 339-341

10.1080/21681805.2017.1322634 | PMID 28580867 Get It

Medical Students Call for Single-Payer National Health Insurance
Harrison, Andrew M. , Harrison, Andrew Marc

Mayo Clinic

Academic Medicine | May 31, 2017 | Volume: 92 | Issue: 6 | Pages: 735-735

10.1097/acm.0000000000001699 | PMID 28557929 Get It

Distinctive microbiomes and metabolites linked with weight loss after gastric bypass, but not gastric banding
Ilhan, Zehra Esra , DiBaise, John K. , Hoyt, David , Marcus, Andrew K. , Krajmalnik‐Brown, Rosa , Hoyt, David W , Isern, Nancy , Kang, Dae‐Wook , Crowell, Michael D. , Rittmann, Bruce E.

Mayo Clinic

The ISME Journal | May 26, 2017 | Volume: 11 | Issue: 9 | Pages: 2047-2058

10.1038/ismej.2017.71 | PMID 28548658 Get It

Abstract Roux-en-Y gastric bypass (RYGB) and laparoscopic adjustable gastric banding (LAGB) are anatomically different bariatric operations. RYGB achieves greater weight loss compared with LAGB. Changes in the gut microbiome have been documented after RYGB, but not LAGB, and the microbial contribution to sustainable surgical weight loss warrants further evaluation. We hypothesized that RYGB imposes greater changes on the microbiota and its metabolism than LAGB, and that the altered microbiota may contribute to greater weight loss. Using multi-omic approaches, we analyzed fecal microbial community structure and metabolites of pre-bariatric surgery morbidly obese (PreB-Ob), normal weight (NW), post-RYGB, and post-LAGB participants. RYGB microbiomes were significantly different from those from NW, LAGB and PreB-Ob. Microbiome differences between RYGB and PreB-Ob populations were mirrored in their metabolomes. Diversity was higher in RYGB compared with LAGB, possibly because of an increase in the abundance of facultative anaerobic, bile-tolerant and acid-sensible microorganisms in the former. Possibly because of lower gastric acid exposure, phylotypes from the oral cavity, such as Escherichia, Veillonella and Streptococcus, were in greater abundance in the RYGB group, and their abundances positively correlated with percent excess weight loss. Many of these post-RYGB microorganisms are capable of amino-acid fermentation. Amino-acid and carbohydrate fermentation products—isovalerate, isobutyrate, butyrate and propionate—were prevalent in RYGB participants, but not in LAGB participants. RYGB resulted in greater alteration of the gut microbiome and metabolome than LAGB, and RYGB group exhibited unique microbiome composed of many amino-acid fermenters, compared with nonsurgical controls.
Predictive models in the diagnosis and treatment of autoimmune epilepsy
Dubey, Divyanshu , Singh, Jaysingh , Pittock, Sean J. , Flanagan, Eoin P. , Lennon, Vanda A. , Tillema, Jan‐Mendelt , Shin, Cheolsu, So, Elson, Cascino, Gregory D. , Wingerchuk, Dean M. , Hoerth, Matthew T., Shih, Jerry J. , Nickels, Katherine , McKeon, Andrew , Pittock, S J , Britton, Jeffrey W. , Wirrell, Elaine , So, Elson L., Flanagan, E P , McKeon, Andrew , Dubey, Divyanshu , Nickels, Katherine C

Mayo Clinic

Epilepsia | May 26, 2017 | Volume: 58 | Issue: 7 | Pages: 1181-1189

10.1111/epi.13797 | PMID 28555833 Get It

Summary Objective To validate predictive models for neural antibody positivity and immunotherapy response in epilepsy. Methods We conducted a retrospective study of epilepsy cases at Mayo Clinic (Rochester‐ MN ; Scottsdale‐ AZ , and Jacksonville‐ FL ) in whom autoimmune encephalopathy/epilepsy/dementia autoantibody testing profiles were requested (06/30/2014‐06/30/2016). An Antibody Prevalence in Epilepsy ( APE ) score, based on clinical characteristics, was assigned to each patient. Among patients who received immunotherapy, a Response to Immunotherapy in Epilepsy ( RITE ) score was assigned. Favorable seizure outcome was defined as >50% reduction of seizure frequency at the first follow‐up . Results Serum and cerebrospinal fluid (CSF) from 1,736 patients were sent to the Mayo Clinic Neuroimmunology Laboratory for neural autoantibody evaluation. Three hundred eighty‐seven of these patients met the diagnostic criteria for epilepsy. Central nervous system (CNS)–specific antibodies were detected in 44 patients. Certain clinical features such as new‐onset epilepsy, autonomic dysfunction, viral prodrome, faciobrachial dystonic seizures/oral dyskinesia, inflammatory CSF profile, and mesial temporal magnetic resonance imaging (MRI) abnormalities had a significant association with positive antibody results. A significantly higher proportion of antibody‐positive patients had an APE score ≥4 (97.7% vs. 21.6%, p < 0.01). Sensitivity and specificity of an APE score ≥4 to predict presence of specific neural auto‐antibody were 97.7% and 77.9%, respectively. In the subset of patients who received immunotherapy (77), autonomic dysfunction, faciobrachial dystonic seizures/oral dyskinesia, early initiation of immunotherapy, and presence of antibodies targeting plasma membrane proteins (cell‐surface antigens) were associated with favorable seizure outcome. Sensitivity and specificity of a RITE score ≥7 to predict favorable seizure outcome were 87.5% and 83.8%, respectively. Significance APE and RITE scores can aid diagnosis, treatment, and prognostication of autoimmune epilepsy. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here .
Right ventricular pacemaker lead position is associated with differences in long‐term outcomes and complications
Witt, Chance M. , Lenz, Charles J., Shih, Henry, Ebrille, Elisa , Rosenbaum, Andrew , Zyl, Martin van , Aung, Htin , Manocha, Kevin K. , Deshmukh, Abhishek , Hodge, David O. , Mulpuru, Siva K. , Cha, Yong‐Mei , Espinosa, Raúl E. , Asirvatham, Samuel J. , McLeod, Christopher J. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 25, 2017 | Volume: 28 | Issue: 8 | Pages: 924-930

10.1111/jce.13256 | PMID 28543771 Get It

AbstractIntroductionCardiac pacing from the right ventricular apex is associated with detrimental long‐term effects and nonapical pacing locations may be associated with improved outcomes. There is little data regarding complications with nonapical lead positions. The aim of this study was to assess long‐term outcomes and lead‐related complications associated with differing ventricular lead tip position.Methods and resultsAll adult patients who underwent dual‐chamber pacemaker implantation from 2004 to 2014 were included if they had postprocedure chest radiographs amenable to lead position determination. Long‐term outcomes and lead‐related complication rates were recorded. These were compared at 5 years between: (1) apical and septal leads, (2) apical and nonseptal nonapical (NSNA), and (3) apical and septal with >40% ventricular pacing. We retrospectively evaluated 3,450 patients, which included 238 with a septal position and 733 with NSNA lead positions. Septal lead position was associated with a lower mortality compared to apical leads (24% vs. 31%, P = 0.02). In patients with greater than 40% pacing, septal leads were associated with significantly higher rates of incident atrial fibrillation compared to apical leads (49% vs. 34%, P = 0.04). NSNA positions were associated with a significantly higher rate of lead dislodgement (4% vs. 2%, P = 0.005) and need for revision (8% vs. 5%, P = 0.005).ConclusionsSeptal pacemaker lead position is associated with a lower mortality compared to apically placed leads, but a higher incidence of atrial fibrillation with higher percentage ventricular pacing. NSNA lead locations are associated with more complications and should be avoided.
Analyses of thrombi in acute ischemic stroke: A consensus statement on current knowledge and future directions
Andersson, Tommy , Baxter, Blaise, Brouwer, Patrick A. , Brinjikji, Waleed , Costalat, Vincent , Dávalos, Antoni , Demchuk, Andrew M. , Dippel, Diederik W.J. , Fischer, Urs , Gilvarry, Michael , Gounis, Matthew J. , Gralla, Jan , Jansen, Olav , Kallmes, David F. , Khatri, Pooja , López‐Cancio, Elena , Majoie, Charles B.L.M. , Marquering, Henk A. , Narata, Ana Paula , Siddiqui, Adnan H. , Szikora, István , Vale, David, Hacke, Werner , Liebeskind, David S. , Kallmes, David, De Meyer, Simon F , Bendszus, Martin , Campbell, Bruce , Fiehler, Jens , Jovin, Tudor G. , Lees, Kennedy R. , Nogueira, Raul G. , Ringleb, Peter Arthur , Kummer, Rüdiger von , Yoo, Albert J. , Liebeskind, David S. , Siddiqui, Adnan H , Szikora, Istvan , Andersson, Tommy , Demchuk, Andrew M , Brouwer, Patrick , Fischer, Urs , Marquering, Henk A , Majoie, Charles B L M , Khatri, Pooja

Mayo Clinic

International Journal of Stroke | May 23, 2017 | Volume: 12 | Issue: 6 | Pages: 606-614

10.1177/1747493017709671 | PMID 28534706 Get It

Limited data exist on clot composition and detailed characteristics of arterial thrombi associated with large vessel occlusion in acute ischemic stroke. Advances in endovascular thrombectomy and related imaging modalities have created a unique opportunity to analyze thrombi removed from cerebral arteries. Insights into thrombus composition, etiology, physical properties and neurovascular interactions may lead to future advancements in acute ischemic stroke treatment and improved clinical outcomes. Advances in imaging techniques may enhance clot characterization and inform therapeutic decision-making prior to treatment and reveal stroke etiology to guide secondary prevention. Current imaging techniques can provide some information about thrombi, but there remains much to evaluate about relationships that may exist among thrombus composition, occlusion characteristics and treatment outcomes. Improved pathophysiological characterization of clot types, their properties and how these properties change over time, together with clinical correlates from ongoing studies, may facilitate revascularization with thrombolysis and thrombectomy. Interdisciplinary approaches covering clinical, engineering and scientific aspects of thrombus research will be key to advancing the understanding of thrombi and improving acute ischemic stroke therapy. This consensus statement integrates recent research on clots and thrombi retrieved from cerebral arteries and provides a rationale for further analyses, including current opportunities and limitations.
Polycystic Kidney Disease without an Apparent Family History
Iliuta, Ioan-Andrei, Kalatharan, Vinusha , Wang, Kairong , Gall, Émilie Cornec-Le , Conklin, John , Pourafkari, Marina, Borgo, Alessia C., He, Ning , Song, Xuewen , Heyer, Christina M., Senum, Sarah R. , Paterson, Andrew D. , Harris, Peter C. , Khalili, Korosh , Pei, York , Cornec-Le Gall, Emilie, Ting, Ryan S. , Chen, Chen , Hwang, Young‐Hwan , Harris, Peter C , Paterson, Andrew , Senum, Sarah R , Cornec-Le Gall, Emilie

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2017 | Volume: 28 | Issue: 9 | Pages: 2768-2776

10.1681/asn.2016090938 | PMID 28522688 Get It

The absence of a positive family history (PFH) in 10%–25% of patients poses a diagnostic challenge for autosomal dominant polycystic kidney disease (ADPKD). In the Toronto Genetic Epidemiology Study of Polycystic Kidney Disease, 210 affected probands underwent renal function testing, abdominal imaging, and comprehensive PKD1 and PKD2 mutation screening. From this cohort, we reviewed all patients with and without an apparent family history, examined their parental medical records, and performed renal imaging in all available parents of unknown disease status. Subsequent reclassification of 209 analyzed patients revealed 72.2% (151 of 209) with a PFH, 15.3% (32 of 209) with de novo disease, 10.5% (22 of 209) with an indeterminate family history, and 1.9% (four of 209) with PFH in retrospect. Among the patients with de novo cases, we found two families with germline mosaicism and one family with somatic mosaicism. Additionally, analysis of renal imaging revealed that 16.3% (34 of 209) of patients displayed atypical PKD, most of which followed one of three patterns: asymmetric or focal PKD with PFH and an identified PKD1 or PKD2 mutation (15 of 34), asymmetric and de novo PKD with proven or suspected somatic mosaicism (seven of 34), or focal PKD without any identifiable PKD1 or PKD2 mutation (eight of 34). In conclusion, PKD without an apparent family history may be due to de novo disease, missing parental medical records, germline or somatic mosaicism, or mild disease from hypomorphic PKD1 and PKD2 mutations. Furthermore, mutations of a newly identified gene for ADPKD, GANAB , and somatic mosaicism need to be considered in the mutation-negative patients with focal disease.